Lexaria Bioscience to Receive New Patents in Four Markets

Global innovator in drug delivery platforms, Lexaria Bioscience (Nasdaq: LEXX), has received notifications of four new patents either awarded or allowed. The new patents cover Japan, Australia, Canada and the United States.

Lexaria believes that its US patent, Compositions and Methods for Treating Hypertension, could be of particular importance in relation to its expected upcoming FDA Investigational New Drug (IND) application.


 In Japan, Lexaria has received a new patent under its Patent Family #3: Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Active Agents.

In Australia, the company received a new patent under its Patent Family #18: Compositions and Methods for Enhanced Delivery of Antiviral Agents.

In Canada, a new patent under Lexaria’s Patent Family #8: Compositions Infused With Nicotine Compounds and Methods of Use Thereof has been allowed.

In the US, a new patent under Patent Family #21: Compositions and Methods for Treating Hypertension has been allowed.

After the awarding of these patents, Lexaria’s total patent portfolio will have grown to 32 granted patents worldwide.

 About Lexaria Bioscience

Lexaria Bioscience’s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients enter the bloodstream through oral delivery. DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 28 patents granted and many patents pending worldwide.


This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Read Full Disclaimer

Share This Article


About the Author

Lexaria Bioscience to Receive New Patents in Four Markets

Editor Prism MarketView